Status:

COMPLETED

The Effect of the Low Fodmap Diet in Children With Autism Spectrum Disorders

Lead Sponsor:

Ohio State University

Conditions:

Autism Spectrum Disorder

Eligibility:

All Genders

6-17 years

Phase:

NA

Brief Summary

This study assesses the effect of the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet on gastrointestinal (GI) and behavioral problems in children with auti...

Detailed Description

In this study, participants were children with autism spectrum disorder (ASD) ages 6-17 years. Children with ASD were randomized to the low FODMAP diet or habitual diet for 2 weeks. At baseline and af...

Eligibility Criteria

Inclusion

  • 6-17 age range
  • Diagnosed with autism spectrum disorder
  • Parent/Caregiver report of constipation and /or abdominal pain. • ROME IV criteria was utilized to identify constipation (defined as the presence of two of more of the following symptoms: Two or fewer stools per week, at least 1 episode of fecal incontinence per week, history of retentive posturing or excessive volitional stool retention, history of painful or hard bowel movements, presence of a large fecal mass in the rectum, history of large diameter stools that can obstruct the toilet) • ROME IV criteria was utilized to identify abdominal pain (defined as the fulfilled at least 4 times per month and include all of the following: episodic or continuous abdominal pain that does not occur solely during physiologic events (eg, eating, menses), insufficient criteria for irritable bowel syndrome, functional dyspepsia, or abdominal migraine, the abdominal pain cannot be fully explained by another medical condition)

Exclusion

  • Under 6 and over 17 years old
  • Having a specific restrictive diet to treat allergies or a specific chronic disease - Any history of abdominal surgeries
  • Any history of chronic physiological GI disorders such as celiac, inflammatory bowel disease, eosinophilic esophagitis.
  • Any chronic condition that may impact GI function such as thyroid disease, cystic fibrosis, or cardiac abnormalities

Key Trial Info

Start Date :

January 3 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 30 2019

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT04054349

Start Date

January 3 2019

End Date

July 30 2019

Last Update

August 13 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Ohio State University Nisonger Center

Columbus, Ohio, United States, 43210